Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Close UK Development Unit
February 10, 2016
- Otsuka Licenses US Rights for PDE4 Inhibitor to Medimetriks
February 10, 2016
- Ethical Drug Sales Up 5.7% in December: Crecon Report
February 10, 2016
- Gilead, Bristol Take Quantum Leaps in 2015, Lilly Logs Double-Digit Growth: IMS
February 10, 2016
- Japan Sales of “Huge Seller” Quartet Each Break 110 Billion Yen in 2015: IMS
February 10, 2016
- Mundipharma Gearing Up for Full-Blown Oncology Business in Japan
February 9, 2016
- AZ Posts Japan Sales of US$2 Billion in 2015, Down 9% in Actual Terms
February 9, 2016
- Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
February 9, 2016
- PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
February 8, 2016
- Takeda Expands ADC Collaboration with US Startup Mersana
February 5, 2016
- FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
February 5, 2016
- Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
February 5, 2016
- BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
February 5, 2016
- Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
February 5, 2016
- Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
February 4, 2016
- Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
February 4, 2016
- Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
February 4, 2016
- Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
February 4, 2016
- Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
February 4, 2016
- Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…